| Sanjit K Dutta, MD | |
|
546 N Jefferson Ln, Spokane, WA 99201-7104 | |
| (509) 624-0111 | |
| (509) 227-7070 |
| Full Name | Sanjit K Dutta |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 36 Years |
| Location | 546 N Jefferson Ln, Spokane, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881610038 | NPI | - | NPPES |
| P00033177 | Other | MN RR | |
| HP39094 | Other | HEALTHPARTNERS | |
| 0405796 | Other | MEDICA | |
| 1034961 | Other | PREFERREDONE | |
| 1875555 | Other | AMERICAS PPO | |
| 23358 | Other | ND | ND BC |
| 595S1DU | Other | MN BC | |
| 889696800 | Medicaid | MN |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Vna Home Health | Spokane, WA | Home health agency |
| Sunshine Home Health Care | Spokane, WA | Home health agency |
| Hospice Of Spokane | Spokane, WA | Hospice |
| Prov Sacred Hrt Med Ctr & Childs Hosp. | Spokane, WA | Hospital |
| Providence Holy Family Hospital | Spokane, WA | Hospital |
| Touchmark On South Hill Nursing | Spokane, WA | Nursing home |
| Rockwood South Hill | Spokane, WA | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Health And Services Washington | 0345139929 | 687 |
| Multicare Health System | 7719899897 | 1704 |
News Archive
Rheumatoid arthritis patients treated with biologic response modifiers for at least 6 months do not have a greater risk for malignancy than those given other disease-modifying drugs or placebo, conclude US and Spanish researchers.
Because mice do not respond to immunomodulatory drugs, preclinical therapeutic and safety studies of the effects of IMiDs have not been possible in existing types of mice.
ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today it has entered into a collaboration in which Cephalon Australia (a wholly owned subsidiary of Cephalon, Inc.) will apply ImmunGene's interferon payload technology to up to six of its new drug targets for cancers.
The microbial population in the air of the New York City subway system is nearly identical to that of ambient air on the city streets. This research, published ahead of print in the journal Applied and Environmental Microbiology, establishes an important baseline, should it become necessary to monitor the subway's air for dispersal of potentially dangerous microbes.
› Verified 4 days ago
| Entity Name | Multicare Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497766638 PECOS PAC ID: 7719899897 Enrollment ID: O20031105000760 |
News Archive
Rheumatoid arthritis patients treated with biologic response modifiers for at least 6 months do not have a greater risk for malignancy than those given other disease-modifying drugs or placebo, conclude US and Spanish researchers.
Because mice do not respond to immunomodulatory drugs, preclinical therapeutic and safety studies of the effects of IMiDs have not been possible in existing types of mice.
ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today it has entered into a collaboration in which Cephalon Australia (a wholly owned subsidiary of Cephalon, Inc.) will apply ImmunGene's interferon payload technology to up to six of its new drug targets for cancers.
The microbial population in the air of the New York City subway system is nearly identical to that of ambient air on the city streets. This research, published ahead of print in the journal Applied and Environmental Microbiology, establishes an important baseline, should it become necessary to monitor the subway's air for dispersal of potentially dangerous microbes.
› Verified 4 days ago
| Entity Name | Rockwood Clinic Ps |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417953787 PECOS PAC ID: 8527976513 Enrollment ID: O20031117000912 |
News Archive
Rheumatoid arthritis patients treated with biologic response modifiers for at least 6 months do not have a greater risk for malignancy than those given other disease-modifying drugs or placebo, conclude US and Spanish researchers.
Because mice do not respond to immunomodulatory drugs, preclinical therapeutic and safety studies of the effects of IMiDs have not been possible in existing types of mice.
ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today it has entered into a collaboration in which Cephalon Australia (a wholly owned subsidiary of Cephalon, Inc.) will apply ImmunGene's interferon payload technology to up to six of its new drug targets for cancers.
The microbial population in the air of the New York City subway system is nearly identical to that of ambient air on the city streets. This research, published ahead of print in the journal Applied and Environmental Microbiology, establishes an important baseline, should it become necessary to monitor the subway's air for dispersal of potentially dangerous microbes.
› Verified 4 days ago
| Entity Name | Providence Health & Services Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194099390 PECOS PAC ID: 0345139929 Enrollment ID: O20040311001453 |
News Archive
Rheumatoid arthritis patients treated with biologic response modifiers for at least 6 months do not have a greater risk for malignancy than those given other disease-modifying drugs or placebo, conclude US and Spanish researchers.
Because mice do not respond to immunomodulatory drugs, preclinical therapeutic and safety studies of the effects of IMiDs have not been possible in existing types of mice.
ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today it has entered into a collaboration in which Cephalon Australia (a wholly owned subsidiary of Cephalon, Inc.) will apply ImmunGene's interferon payload technology to up to six of its new drug targets for cancers.
The microbial population in the air of the New York City subway system is nearly identical to that of ambient air on the city streets. This research, published ahead of print in the journal Applied and Environmental Microbiology, establishes an important baseline, should it become necessary to monitor the subway's air for dispersal of potentially dangerous microbes.
› Verified 4 days ago
| Entity Name | Department Of Veterans Affairs Spokane Veterans Home |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851381032 PECOS PAC ID: 0345234456 Enrollment ID: O20040412001531 |
News Archive
Rheumatoid arthritis patients treated with biologic response modifiers for at least 6 months do not have a greater risk for malignancy than those given other disease-modifying drugs or placebo, conclude US and Spanish researchers.
Because mice do not respond to immunomodulatory drugs, preclinical therapeutic and safety studies of the effects of IMiDs have not been possible in existing types of mice.
ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today it has entered into a collaboration in which Cephalon Australia (a wholly owned subsidiary of Cephalon, Inc.) will apply ImmunGene's interferon payload technology to up to six of its new drug targets for cancers.
The microbial population in the air of the New York City subway system is nearly identical to that of ambient air on the city streets. This research, published ahead of print in the journal Applied and Environmental Microbiology, establishes an important baseline, should it become necessary to monitor the subway's air for dispersal of potentially dangerous microbes.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sanjit K Dutta, MD Po Box 421, Liberty Lake, WA 99019-0421 Ph: (509) 624-0111 | Sanjit K Dutta, MD 546 N Jefferson Ln, Spokane, WA 99201-7104 Ph: (509) 624-0111 |
News Archive
Rheumatoid arthritis patients treated with biologic response modifiers for at least 6 months do not have a greater risk for malignancy than those given other disease-modifying drugs or placebo, conclude US and Spanish researchers.
Because mice do not respond to immunomodulatory drugs, preclinical therapeutic and safety studies of the effects of IMiDs have not been possible in existing types of mice.
ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today it has entered into a collaboration in which Cephalon Australia (a wholly owned subsidiary of Cephalon, Inc.) will apply ImmunGene's interferon payload technology to up to six of its new drug targets for cancers.
The microbial population in the air of the New York City subway system is nearly identical to that of ambient air on the city streets. This research, published ahead of print in the journal Applied and Environmental Microbiology, establishes an important baseline, should it become necessary to monitor the subway's air for dispersal of potentially dangerous microbes.
› Verified 4 days ago
Ms. Deirdre Marie Mooney, MD, MPH Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 122 W 7th Ave Ste 450, Spokane, WA 99204 Phone: 509-455-8820 | |
Dr. Rebecca Raluca Teona Muntean, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 820 S Mcclellan St, Suite 200, Spokane, WA 99204 Phone: 509-747-1144 Fax: 509-455-4166 | |
Dr. Arnold L Klipstein, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 801 W 5th Ave Ste 309, Spokane, WA 99204 Phone: 509-838-2531 Fax: 509-755-6580 | |
Dr. Joseph W Davis, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 104 W 5th Ave Ste 200w, Spokane, WA 99204 Phone: 509-744-3750 Fax: 509-744-3969 | |
John G Peterson, MD, FACC Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 212 E Central Ave, Suite 240, Spokane, WA 99208 Phone: 509-455-8820 Fax: 509-838-4978 | |
Elizabeth C Ho, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 546 N Jefferson Ln Ste 200, Spokane, WA 99201 Phone: 509-625-3700 Fax: 509-625-3747 | |
Michael F. Kestell, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 105 W 8th Ave, Suite 6010, Spokane, WA 99204 Phone: 509-838-5950 Fax: 509-838-5961 |